logo
  

Celyad Oncology Discontinues Autologous CAR T Candidate CYAD-01; CYCLE-1 CYAD-02 Trial Ongoing

Celyad Oncology SA (CYAD), a clinical-stage biotechnology company focused on chimeric antigen receptor T cell or CAR T therapies for cancer, issued Monday updates on allogeneic and autologous CAR T Programs.

The updates from the company's shRNA-based anti-B cell maturation antigen or BCMA allogeneic CAR T candidate, CYAD-211, and autologous NKG2D receptor-based CAR T candidates, CYAD-01 and CYAD-02, were virtually presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

The company said it is disappointed in its update from the Phase 1 THINK trial for first-generation, autologous CAR T candidate CYAD-01 and discontinues its development based on clinical futility observed to date from the Phase 1 THINK trial.

Meanwhile, preliminary data from CYCLE-1 trial evaluating next-generation autologous CYAD-02 in r/r AML / MDS patients showed encouraging clinical signals, including a high-risk MDS patient treated at dose level 3 who achieved an objective marrow complete response. The company said dose level 3 cohort of the CYCLE-1 trial is ongoing.

The company noted the dosing of first patient with CYAD-211 Phase 1 IMMUNICY-1 trial. Preclinical results for CYAD-211 for multiple myeloma showed robust antitumor activity with no demonstrable evidence of Graft-versus-Host Disease.

Filippo Petti, Chief Executive Officer of Celyad Oncology, said, "While we are disappointed by the latest update from the Phase 1 THINK trial for CYAD-01, we are encouraged by the initial clinical results from our next-generation CYAD-02 candidate for the treatment of patients with relapsed or refractory AML and MDS and look forward to future updates from the CYCLE-1 trial."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Oilfield services company Schlumberger Ltd. reported Friday a profit for the fourth quarter that surged 61 percent from last year, reflecting 13 percent higher revenues amid growth across all segments and regions. Both adjusted earnings per share and quarterly revenues topped analysts' estimates. Twitter Inc. has launched a new feature to allow some users of its Blue subscriber service to keep non-fungible tokens or NFTs as their profile pictures. Twitter Blue is now available in the US, Canada, Australia, and New Zealand. NFT is a crypto token, which is non-fungible, meaning that it can neither be transferred like money nor replaced with something else. Frozen Food Development is recalling specific lots of Lidl branded 12-ounce packages of Frozen Chopped Spinach citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The product comes in 12-ounce poly bags, and items included in the recall are marked with lot # R17742 or R17963 on the back of the poly bag with a best by date of 09/10/23.
RELATED NEWS
Follow RTT